FUL Reports Q2 2026 Earnings

H.B.

Fuller (NYSE: FUL ) reported second-quarter financial results on Thursday.

The transcript from the company's second-quarter earnings call has been provided below.

This transcript is brought to you APIs.

For real-time access to our entire catalog, please visit for a consultation.

Access the full call at Summary H.B.

Fuller reported a 5.8% increase in revenue year-on-year for Q2 2026, with organic growth of 2.6% driven by a 3% increase in pricing, partially offset by lower volumes.

The company announced its plan to acquire Advanced Medical Solutions (AMS) for approximately 715 million pounds, aiming to transform its portfolio towards higher growth, higher margin sectors.

Adjusted EBITDA for the quarter was $181 million, up 9% year-on-year, with an EBITDA margin expansion of 70 basis points to 19.1%.

H.B.

Fuller expects its adjusted EBITDA for fiscal 2026 to be between $650 million and $675 million, with EPS expected to range from $4.60 to $4.90.

Strategically, the acquisition of AMS is expected to enhance H.B.

Fuller's footprint in the medical market, which is seen as a non-discretionary, high-growth sector with significant barriers to entry.

Operationally, the company managed to maintain supply continuity despite petrochemical supply chain disruptions, attributing this to its global sourcing capabilities.

The company plans to leverage synergies from the AMS acquisition, expecting $55 million in run-rate synergies, and aims to achieve a net leverage target range of 2.5 to 3 times within two years post-acquisition.

Management reaffirmed its commitment to disciplined capital allocation and maintaining strong shareholder value creation, despite the temporary increase in leverage due to the AMS acquisition.

Full Transcript OPERATOR Hello and welcome to the H.B.

Fuller second quarter 2026 earnings conference call.

All lines have been placed on mute to prevent any background noise.

After the speaker's remarks, there will be a question and answer session, and if you would like to ask a question during this time, please press star 1 on your telephone keypad.

I would now like to turn the conference over to Scott Jensen, Director of Investor Relations.

You may begin.

Scott Jensen, Director of Investor Relations Thank you, operator.

Welcome to H.B.

Fuller's second quarter 2026 investor conference call.

Presenting today are Celeste Mastin, President and Chief Executive Officer, and John Corcoran, Executive Vice President and Chief Financial Officer.

After our prepared remarks, we will have a question and answer session.

Before we begin, let me remind everyone that our comments today will include references to certain non-GAAP financial measures.

These measures are supplemental to the results determined in accordance with GAAP.

We believe that these measures are useful to investors in understanding our operating performance and to compare our performance with other companies.

Reconciliation of non-GAAP measures to the nearest GAAP measure are included in our earnings release unless otherwise noted.

Comments about revenue refer to organic revenue, and comments about EBITDA and profit margins refer to adjusted non-GAAP measures.

We will also be making forward-looking statements during this call.

These statements are based on current expectations and assumptions that are subject to risks and uncertainties.

Actual results could differ materially from these expectations due to factors covered in our earnings release, comments made during this call, and the risk factors detailed in our filings with the SEC, all of which are available on our website at investors.hbfuller.com.

During this call, we will be referencing information from our second quarter earnings release along with the press release related to our announced offer to acquire Advanced Medical Solutions.